Literature DB >> 24070006

Activity of ceftaroline and comparator agents tested against contemporary Gram-positive and -negative (2011) isolates collected in Europe, Turkey, and Israel.

Mariana Castanheira, Ronald N Jones, Helio S Sader.   

Abstract

The activity of ceftaroline was tested against 8233 isolates mainly collected from bloodstream, urinary, respiratory and skin and soft tissue specimens in European medical centers during 2011. This cephalosporin displayed activity against Staphylococcus aureus (MIC(50), 0·25 mg/l), with greater activity against MRSA (MIC(50), 1 mg/l) than other β-lactams tested. Against Streptococcus pneumoniae, including penicillin-resistant strains, other streptococcal groups and Haemophilus spp., ceftaroline was highly active and MIC90 values ranged from ≤0·015 to 0·12 mg/l. Ceftaroline, like other cephalosporins, had limited activity against ESBL-phenotype Enterobacteriaceae, but showed good activity against isolates not displaying an ESBL-phenotype. Ceftaroline remains very active against MRSA and other organisms than could be associated with its approved indications in the EU (complicated skin and soft tissue infections and community-acquired pneumonia).

Entities:  

Keywords:  Ceftaroline,; Europe,; MRSA,; Surveillance

Mesh:

Substances:

Year:  2013        PMID: 24070006     DOI: 10.1179/1973947813Y.0000000135

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  6 in total

Review 1.  Ceftaroline fosamil: a novel broad-spectrum cephalosporin.

Authors:  J A Bazan; S I Martin
Journal:  Drugs Today (Barc)       Date:  2010-10       Impact factor: 2.245

2.  Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007-09).

Authors:  Mariana Castanheira; Rodrigo E Mendes; Leah N Woosley; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2011-03-18       Impact factor: 5.790

3.  Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program.

Authors:  Robert K Flamm; Helio S Sader; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2012-04-02       Impact factor: 5.191

Review 4.  Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia.

Authors:  Mical Paul; Galia Kariv; Elad Goldberg; Maria Raskin; Hila Shaked; Rawi Hazzan; Zmira Samra; Dina Paghis; Jihad Bishara; Leonard Leibovici
Journal:  J Antimicrob Chemother       Date:  2010-10-14       Impact factor: 5.790

Review 5.  Methicillin-resistant Staphylococcus aureus: the European landscape.

Authors:  Alan P Johnson
Journal:  J Antimicrob Chemother       Date:  2011-05       Impact factor: 5.790

Review 6.  Has the era of untreatable infections arrived?

Authors:  David M Livermore
Journal:  J Antimicrob Chemother       Date:  2009-09       Impact factor: 5.790

  6 in total
  6 in total

Review 1.  Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

2.  In Vitro Activity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program.

Authors:  Douglas J Biedenbach; Richard A Alm; Sushmita D Lahiri; Edina Reiszner; Daryl J Hoban; Daniel F Sahm; Samuel K Bouchillon; Jane E Ambler
Journal:  Antimicrob Agents Chemother       Date:  2015-10-26       Impact factor: 5.191

3.  A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities.

Authors:  Matthew Dryden; Yingyuan Zhang; David Wilson; Joseph P Iaconis; Jesus Gonzalez
Journal:  J Antimicrob Chemother       Date:  2016-09-01       Impact factor: 5.790

4.  Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections.

Authors:  Shampa Das; Jianguo Li; Joseph Iaconis; Diansong Zhou; Gregory G Stone; Jean Li Yan; David Melnick
Journal:  J Antimicrob Chemother       Date:  2019-02-01       Impact factor: 5.790

5.  Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h.

Authors:  Karen Cheng; Rienk Pypstra; Jean Li Yan; Jennifer Hammond
Journal:  J Antimicrob Chemother       Date:  2019-04-01       Impact factor: 5.790

6.  The use of extrapolation based on modeling and simulation to support high-dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft-tissue infections.

Authors:  Phylinda L S Chan; Lynn McFadyen; Andrea Quaye; Heidi Leister-Tebbe; Victoria M Hendrick; Jennifer Hammond; Susan Raber
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-05-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.